Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402719 | 0.80 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2AICAM1 | |
| SCHEMBL6408281 | 0.79 | NPC1 (0.44) | NPC1RAB9AMEN1KMT2AICAM1 | |
| SCHEMBL6400656 | 0.79 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AKDM4C | |
| SCHEMBL8321396 | 0.73 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AICAM1 | |
| SCHEMBL6402201 | 0.72 | KCNJ11 (0.43) | KCNJ11EPHX2KDM4E | |
| SCHEMBL8632096 | 0.71 | ALDH1A1 (0.50) | NPC1RAB9AKDM4CGAA | |
| SCHEMBL6947486 | 0.70 | NPC1 (0.52) | NPC1RAB9AMEN1KMT2AKDM4C | |
| SCHEMBL6400712 | 0.70 | NPC1 (0.59) | NPC1RAB9AMEN1KMT2AKDM4C | |
| SCHEMBL29015324 | 0.70 | NPC1 (0.41) | NPC1RAB9AMEN1KMT2AICAM1 | |
| SCHEMBL1800954 | 0.70 | CREBBP (0.33) | NPC1RAB9AMEN1KMT2AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. | 2003-11-06 | — | — | US | disclosed |
| EP-1032571-B1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1032571-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025714-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | HRH2, TACR1, HRH4 | NPC1 2100/4885RAB9A 2264/4885MEN1 3056/4885 |
| US-20030208079-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | TACR1, HRH2, GRPR | NPC1 1630/4885RAB9A 2593/4885MEN1 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.